Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAT-08: SC-DARIC33 in Relapsed or Refractory CD33+ AML
NCT05105152Phase 1Recruiting
- Sponsor
- Seattle Children's
- Start
- Nov 2021
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DARIC33 in acute myeloid leukemia (AML), sponsored by Seattle Children's. Primary endpoints: Adverse events associated with SC-DARIC33 cell product infusions at 28 days and Ability to successfully manufacture SC-DARIC33 at 28 days. Started Nov 2021; status: recruiting.
02
Drugs
DARIC33
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05105152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105152.